Literature DB >> 15033197

Hip status in cerebral palsy after one year of continuous intrathecal baclofen infusion.

Linda E Krach1, Robert L Kriel, Richard C Gilmartin, Dale M Swift, Bruce B Storrs, Rick Abbott, John D Ward, Karen K Bloom, William H Brooks, Joseph R Madsen, John F McLaughlin, Joseph M Nadell.   

Abstract

The purpose of this study was to assess whether reduction of muscle tone by continuous intrathecal baclofen infusion affects the progression of hip subluxation in persons with cerebral palsy. This prospective, open-label, case series was conducted at multiple specialty referral centers. There were 33 subjects, ages 4 to 31 years. All had a pretreatment lower extremity Ashworth score of >/=3; all subjects had a significant reduction in tone after a bolus injection of intrathecal baclofen and received an implanted pump for continuous delivery of intrathecal baclofen. Subjects had hip x-rays before and 1 year after pump implantation. The primary outcome measure was change in absolute hip migration percentage. One third of the hips had an increase of absolute migration percentage of 5% or more; 12% of the hips had a decrease of migration percentage of 5% or more. Change of migration percentage class was used as a second outcome criterion. 90.9% of hips manifested no deterioration or had improvement of their migration percentage class during the year of intrathecal baclofen therapy. The observed changes were not associated with the subject's age or the severity of cerebral palsy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15033197     DOI: 10.1016/j.pediatrneurol.2003.08.006

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  7 in total

Review 1.  Intrathecal baclofen for childhood hypertonia.

Authors:  A Leland Albright
Journal:  Childs Nerv Syst       Date:  2007-06-29       Impact factor: 1.475

Review 2.  Intrathecal baclofen, selective dorsal rhizotomy, and extracorporeal shockwave therapy for the treatment of spasticity in cerebral palsy: a systematic review.

Authors:  Amogh Kudva; Mickey E Abraham; Justin Gold; Neal A Patel; Julian L Gendreau; Yehuda Herschman; Antonios Mammis
Journal:  Neurosurg Rev       Date:  2021-04-19       Impact factor: 3.042

3.  The role for hip surveillance in children with cerebral palsy.

Authors:  Benjamin Shore; David Spence; Hk Graham
Journal:  Curr Rev Musculoskelet Med       Date:  2012-06

4.  [Neuromodulation of spasticity in children by intrathecal baclofen].

Authors:  R Cumlivski; G Redl; W Strobl; W Girsch; A Krebs; P Machowetz
Journal:  Schmerz       Date:  2009-12       Impact factor: 1.107

5.  Prevalence of hip dislocation among children with cerebral palsy in regions with and without a surveillance programme: a cross sectional study in Sweden and Norway.

Authors:  Areej I Elkamil; Guro L Andersen; Gunnar Hägglund; Torarin Lamvik; Jon Skranes; Torstein Vik
Journal:  BMC Musculoskelet Disord       Date:  2011-12-16       Impact factor: 2.362

6.  Intrathecal baclofen therapy in paediatrics: a study protocol for an Australian multicentre, 10-year prospective audit.

Authors:  Kirsty Stewart; Gavin Hutana; Megan Kentish
Journal:  BMJ Open       Date:  2017-06-21       Impact factor: 2.692

Review 7.  Intrathecal baclofen for treating spasticity in children with cerebral palsy.

Authors:  Monika J Hasnat; James E Rice
Journal:  Cochrane Database Syst Rev       Date:  2015-11-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.